The biodistribution of extracellular vesicles (EVs) is a fundamental question in the field of circulating biomarkers, which has recently gained attention. Despite the capabilities of nuclear imaging methods such as single photon emission computed tomography (SPECT), radioisotope labeling of EVs and the use of the aforementioned methods for in vivo studies hardly can be found in the literature. In this paper we describe a novel method for the radioisotope labeling of erythrocyte-derived EVs using the 99m Tctricarbonyl complex. Moreover, the capability of the developed labeling method for in vivo biodistribution studies is demonstrated in a mouse model. We found that the intravenously administered, According to our data, only a minor fraction of the radioactive label became detached from the EVs.
Introduction
Extracellular vesicles (EVs) are recently recognized as key players in many physiological and pathological conditions. [1] [2] [3] [4] [5] [6] EVs are not only present in all human body fluids, but also can be found for example in ocean water 7 and beer 8 , due to the fact that yeasts and other microorganisms also release EVs. The clinical relevance of EVs was first recognized for their diagnostic use as biomarkers of different diseases 5 .
Recently the therapeutic application of EVs is also emerging 9, 10 , for example, the application of dendritic cell (DC) derived exosomes for cancer treatment was recently under investigation in a clinical trial (NCT01159288). Understanding the role of these membrane vesicles in intercellular communication and also their applicability as vehicles for drug delivery requires the investigation of their biodistribution. The in vivo fate of EVs has only been addressed in the last few years, and most studies used fluorescent imaging for this purpose. [11] [12] [13] [14] [15] [16] [17] [18] In these studies EVs were either labeled with a membrane dye 13, 18 or engineered to display a membrane reporter (e.g. Gaussia luciferase), and administered exogenously 15 or utilized endogenously produced, genetically modified EVs (such as GFP-tagged CD63 bearing EVs) 19 . On the other hand, the application of nuclear imaging techniques such as single photon emission computed tomography (SPECT) or positron emission tomography (PET) utilizing isotopically labeled EVs hardly can be found in the literature, despite the fact that these techniques have indisputable advantages over fluorescent imaging regarding quantitative measurement of the biodistribution of the labeled compounds. 20 In this paper we report a novel method for radioisotope labeling of EVs using 99m
Tc-tricarbonyl complex, and demonstrate the applicability of this method for the non-invasive assessment of the biodistribution of erythrocyte-derived EVs using SPECT/CT.
Material and Methods

Preparation of erythrocyte vesicles
Erythrocyte vesicles were isolated from freshly outdated erythrocyte concentrates (Hungarian National Transfusion Service). The erythrocyte concentrate was two-fold diluted in phosphate buffered saline (PBS, Sigma-Aldrich, P4417), and the red blood cells were removed by two centrifugation steps at 1500 x g for 20 minutes at 4 C. EVs in the erythrocyte-free supernatant were concentrated by ultracentrifugation (Thermo Sorvall WX Ultracentrifuge, T-1270 fixed angle rotor) at 130 000 x g for 30 min and washed once with PBS using the same parameters. After re-suspending the EV pellet in PBS, the sample was filtered through a 600 nm polycarbonate filter (Whatman® Nuclepore TM ), and finally snap frozen in 100 μl aliquots using liquid nitrogen and stored at -20 °C until use.
Freeze-Fracture Transmission Electron Microscopy (FF-TEM)
The vesicle sample (1-2 µl) was pipetted onto a gold sample holder, was frozen by plunging it immediately into partially solidified freon for 20 seconds and was stored in liquid nitrogen. Fracturing was performed at -100 °C in a Balzers freeze-fracture device (Balzers BAF 400D, Balzers AG, Vaduz, Liechtenstein). Replicas of the fractured faces etched at -100 °C were made by platinum-carbon shadowing and then cleaned with a water solution of surfactant and washed with distilled water. The replicas were placed on 200 mesh copper grids and examined in a MORGAGNI 268D (FEI, The Netherlands) transmission electron microscope.
Size Exclusion Chromatography combined with Dynamic Light Scattering (SEC-DLS)
SEC-DLS analysis was performed with a Jasco HPLC system (Jasco, Tokyo, Japan) consisting of a PU- 
Purification and concentration of erythrocyte derived EVs
Prior to labeling of the erythrocyte-derived EVs obtained by differential centrifugation, the EV sample was purified using a 10 mL plastic gravity column filled with the same Sepharose CL-2B gel used for the SEC-DLS investigation. 0.5 mL EV sample was introduced onto the column and PBS was used as the eluent. The EV-containing fraction corresponding to the void volume of the column was collected (1 mL) and further concentrated to 0.6 mL by using Vivaspin 500 centrifugal filters with 100 kDa MWCO (Sartorius Stedim Biotech GmbH).
99mTc labeling of the purified erythrocyte derived EVs
Radiolabeling of the erythrocyte-derived EVs was performed with the Tc-tricarbonyl complex only. During the scans the animals were continuously anaesthetized using a mixture of 1-1.5%
isoflurane and medical oxygen. Their body temperature was maintained at 37 o C throughout the scanning.
The SPECT scans started 1 hour after the time of administration, and the acquisition lasted 45 minutes.
To prevent movements, the animals were immobilized in a MultiCellTM Imaging Chamber (Mediso Ltd., The uptake values were measured in the following organs: heart, lungs, kidneys, liver, spleen, and bladder.
Results and Discussion
Fig . 1A shows the TEM images of the platinum-carbon replicas of the freeze-fractured EV sample.
Spherical vesicles within the size range of 80 nm to 300 nm can be observed on these pictures, clearly demonstrating the applicability of the used isolation protocol. SEC-DLS analysis was used to characterize the purity of the EV sample as well as to determine the mean hydrodynamic diameter of the vesicles (Fig.1B) . During the SEC analysis, the EVs were excluded from the pores of the used gel (Sepharose CL-2B), and consequently they are eluted at shorter elution times (at 4.6 min in our case). The on-line DLS detector enabled the characterization of the mean size of the vesicle fraction, which was found to be 188 ± 11 nm (standard deviation). Smaller objects such as lipoproteins and soluble plasma proteins enter the pores of the gel, which results in longer elution times (at 14.3 min in our case). Due to the smaller size of the plasma proteins, their contribution cannot be detected based on the light scattering signal, but the UV absorption clearly indicates their presence in the studied sample.
Contamination by plasma proteins in EV samples is common when using isolation by differential centrifugation only. Therefore our sample was further purified prior to the radioisotope labeling. The purification was performed using the same Sepharose CL-2B gel that was used for the SEC-DLS analysis, but in a preparative manner using a 10 mL plastic tube and a gravity separation protocol. It was recently
shown by Böing et al. that the contamination from high density lipoprotein is less than 5% and from plasma proteins is less than 1% in the purified EV-fraction by using this protocol. 21 The latter also agrees with our previous experience using the Sepharose CL-2B gel.
To the best of our knowledge no literature data is available for the radioisotope labeling of EVs. On the other hand, several approaches exist for the labelling of liposomes, which can be treated as model systems of the EVs due to the fact that the phospholipid bilayer represents the basic structural building block for Tc-pertechnetate is an easy manner of liposome labeling but the radiochemical yield, the specific activity and the stability of the forming complex seems to be very low 33 .
Radiolabeling of artificial exosome-mimetic nanovesicles (ENVs) prepared by extrusion of macrophage cells was recently reported using the 99m Tc-HMPAO method which is an established technique in liposome research. 34 The in vivo biodistribution of ENVs used as model system for real EVs was investigated using SPECT/CT. Although this method can be used in principle to label real EVs, the low labeling efficiency of the HMPAO method at low concentrations in the case of liposomes might hinder the successful labeling of EVs.
In our experiment the novel organometallic aquaion, 99m
Tc-tricarbonyl was used for the radioisotope labeling of the purified EVs. This technique combines the advantages of high specific activity and small size of the labeling compound. 35 Hence it retains the biological activity of the labeled object. The 99m Tctricarbonyl has been used for the labeling of a wide range of biomolecules from small tracer molecules, peptides, and antibodies to liposomes containing a DTPA chelater. 33, 36 The 99m
Tc-tricarbonyl binds to several amino acids such as histidine, methionine, and cysteine, 37 consequently it was assumed that this aquaion will inherently bind to the surface of EVs due to the presence of membrane proteins of the vesicles. After the labeling procedure, the unbound 99m
Tc-tricarbonyl was removed by using desalting columns. The used desalting column removes more than 98% of the free Tc-tricarbonyl according to our previous experience, which also agrees with the specification from the manufacturer. By measuring the activities of the elutes and the columns, a labeling efficiency of 38.8 ± 6.2% was obtained for the erythrocyte derived EVs, which is reasonable, especially if the generally low concentration of EVs is considered. Tc-tricarbonyl as demonstrated by a control measurement with the labeling compound. The real advantage of modern nuclear imaging methods is that the distribution of the labeled objects can be quantified without the need for removing the specific organs. In order to determine the percentage of the radioactivity in the different organs, appropriate VOIs were used. Fig. 3 shows the distribution of the labeled EVs within the different organs as a percentage of the total injected radioactivity (Fig. 3A) and also as standardized uptake value, known as SUV (Fig. 3B) . SUV is defined as the ratio of the tissue radioactivity concentration and the injected activity divided by the body weight (as often used in PET). A major advantage of preclinical SPECT imaging is its ability to produce quantitative results for biodistribution, 38 just like PET imaging. SUV takes into account the volume of the segmented organ and so highlights organs with higher tissue uptake values.
The distribution values for the labeling compound alone are also presented in Fig. 3 . The distributions of the free 99m
Tc-tricarbonyl and that of the labeled EVs differ significantly, which is an evidence of the successful labeling. The radioactivity detected in the bladder (3% of the injected radioactivity), originates from the free Tc-HMPAO method is challenging due to the low radiochemical yield of the method at low EV concentrations 34 .
In summary, a novel method for the radioisotope labeling of erythrocyte-derived EVs using 99m
Tctricarbonyl complex is presented. Special attention was paid to the purity of the EV sample that was achieved by SEC purification. This procedure assured that only EVs were labeled, since the used radiolabel could have also bound to free serum proteins. Acceptable radiochemical yield was achieved by the use of the novel 99m Tc-tricarbonyl complex, which has high affinity to biomolecules. The applicability of the presented radiochemical labeling procedure was demonstrated by in vivo SPECT/CT imaging experiments using a mouse model which also confirmed the in vivo stability of the labeling. The presented method might pave the way for further studies addressing the in vivo fate of EVs using nuclear imaging methods. 
